Comment on: The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
Pediatr Blood Cancer
.
2021 Apr;68(4):e28813.
doi: 10.1002/pbc.28813.
Epub 2020 Nov 16.
Authors
Paige Vicenzi
1
,
Zahra Jiwani
2
,
Ricardo Guirola
3
,
Tyler Hamby
1
4
,
Anish Ray
5
Affiliations
1
Texas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, Texas.
2
Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan.
3
Department of Pediatric Rheumatology, Cook Children's Health Care System, Fort Worth, Texas.
4
Department of Research Operations, Cook Children's Health Care System, Fort Worth, Texas.
5
Department of Pediatric Hematology/Oncology, Cook Children's Health Care System, Fort Worth, Texas.
PMID:
33200506
DOI:
10.1002/pbc.28813
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Interleukin 1 Receptor Antagonist Protein*
Lymphohistiocytosis, Hemophagocytic* / drug therapy
Multiple Organ Failure
Retrospective Studies
Substances
Interleukin 1 Receptor Antagonist Protein